|
Delaware
|
| |
2834
|
| |
38-3317208
|
|
|
(State or other jurisdiction of
incorporation or organization) |
| |
(Primary Standard Industrial
Classification Code Number) |
| |
(I.R.S. Employer
Identification Number) |
|
|
Ryan A. Murr
Melanie E. Gertz Gibson, Dunn & Crutcher LLP 555 Mission Street, Suite 3000 San Francisco, CA 94105 (415) 393-8373 |
| |
Megan C. Timmins
SVP, General Counsel and Secretary Rockwell Medical, Inc. 30142 S. Wixom Road Wixom, Michigan 48393 (248) 960-9009 |
|
|
Large accelerated filer
☐
|
| |
Accelerated filer
☐
|
|
|
Non-accelerated filer
☒
|
| |
Smaller reporting company
☒
|
|
| | | |
Emerging growth company
☐
|
|
| | | | | ii | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 9 | | | |
| | | | | 11 | | | |
| | | | | 11 | | | |
| | | | | 12 | | | |
| | | | | 13 | | |
Selling Stockholder
|
| |
Shares
Beneficially Owned Before this Offering |
| |
Percentage of
Outstanding Shares Beneficially Owned Before this Offering |
| |
Shares to be
Sold in this Offering |
| |
Shares
Beneficially After this Offering |
| |
Percentage of
Outstanding Shares Beneficially Owned After this Offering(1) |
| |||||||||||||||
Armistice Capital Master Fund Ltd.(2)
|
| | | | 19,330,890 | | | | | | 68.2%(3) | | | | | | 11,168,887 | | | | | | 8,162,003 | | | | | | 47.5%(3) | | |
|
SEC registration fee
|
| | | $ | 1,429 | | |
|
Legal fees and expenses
|
| | | | 50,000 | | |
|
Printing and miscellaneous expenses
|
| | | | 3,571 | | |
|
Total
|
| | | $ | 55,000 | | |
|
EXHIBIT
NO |
| |
DESCRIPTION
|
| |||
| | | 10.28* | | | | | |
| | | 10.29# | | | |
Loan and Security Agreement, dated March 16, 2020, by and among the Company, Innovatus
Life Sciences Lending Fund I, LP and the lenders party thereto (Exhibit 10.1 to the Company’s Form 10-Q filed on May 11, 2020). |
|
| | | 10.30 | | | | First Amendment to Loan and Security Agreement, dated September 24, 2021, by and among the Company, Innovatus Life Sciences Lending Fund I, LP and the lenders party thereto (Exhibit 10.1 to the Company’s Form 8-K filed on September 30, 2021) | |
| | | 10.31 | | | | | |
| | | 10.32 | | | | | |
| | | 10.33 | | | | | |
| | | 21.1 | | | | | |
| | | 23.1* | | | | | |
| | | 23.2* | | | | | |
| | | 24.1* | | | | | |
| | | 107.1* | | | | |
| Rockwell Medical, Inc. | | |||
| By: | | | /s/ Russell Ellison | |
| | | |
Russell Ellison
President and Chief Executive Officer |
|
Name
|
| |
Title
|
| |
Date
|
|
/s/ Russell Ellison
Russell Ellison
|
| |
President, Chief Executive Officer and Director
(Principal Executive Officer) |
| |
June 22, 2022
|
|
/s/ Russell Skibsted
Russell Skibsted
|
| |
Chief Financial Officer
(Principal Financial Officer) |
| |
June 22, 2022
|
|
/s/ Paul E. McGarry
Paul E. McGarry
|
| | Principal Accounting Officer | | |
June 22, 2022
|
|
/s/ John G. Cooper
John G. Cooper
|
| | Director | | |
June 22, 2022
|
|
/s/ Robert S. Radie
Robert S. Radie
|
| | Director | | |
June 22, 2022
|
|
/s/ Allen Nissenson
Allen Nissenson
|
| | Director | | |
June 22, 2022
|
|
/s/ Andrea Heslin Smiley
Andrea Heslin Smiley
|
| | Director | | |
June 22, 2022
|
|
/s/ Mark H. Ravich
Mark H. Ravich
|
| | Director | | |
June 22, 2022
|
|